The Glomerular Disease Study & Trial Consortium (GlomCon) aims to bring together clinicians, pathologists, researchers, and biotech innovators to create a scalable network of stakeholders interested in helping patients with glomerular kidney disease. Through this network of collaborations GlomCon aims to make the collective expertise of its members available for discussion of individual cases, provide infrastructure for biomarker studies, enable genomic research, and facilitate clinical trials.

This endeavor benefits everyone. If we can understand better ways to classify these diseases, understand their etiologies, and their responses to existing and new therapies, physicians, the developers of innovative treatments, and most importantly our patients, will all benefit.

The motivation to bring together a large group of experts from various regions and institutions comes from the unparalleled demands in the management of patients with glomerular kidney disease. The glomerulus is one of the most complex inventions of nature. Based on most classification schemes, more than 100 different disorders have been reported to affect its function. Many of these classifications are questionable: too many names obscure common features, etiologies, and potential therapies. With diagnostic uncertainties come therapeutic failures. An almost insurmountable barrier to breakthrough innovation in this field has been the relative scarcity of any given disorder. The majority of specialists and medical centers may not encounter sufficient cases of a given rare disease in a given time period to develop systematic and data driven approaches, let alone comfort with treatment.  The rarity of encounters makes not only the study of disease difficult, but also hinders clinical trials.